Join
Live feed
·
PRReleasevia Quantisnow
Quantum Biopharma Ltd. logo

Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)

ByQuantisnow·Wall Street's wire, on your screen.
QNTM· Quantum Biopharma Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track QNTM (Quantum Biopharma Ltd.) and more on Quantisnow.